Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has announced an exclusive partnership with Sanofi Healthcare India Pvt. Ltd. to distribute Sanofi’s portfolio of pediatric and adult vaccines in India. The agreement grants Dr. Reddy’s exclusive rights to promote and distribute brands such as Hexaxim, Pentaxim, and Menactra, which collectively reported sales of around INR 426 crores. This strategic move positions Dr. Reddy’s as the second-largest vaccine player in the Indian market and continues its commitment to increasing access to healthcare.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
